GSK Gets OTC Mevacor U.S. Marketing Rights In Agreement With Merck

 
• By Jessica Lake

GlaxoSmithKline will have exclusive U.S. marketing rights for what would be a first nonprescription statin, pending FDA approval of Merck's Rx-to-OTC switch application for its Mevacor cholesterol-lowering drug

More from Archive

More from Pink Sheet